Pfizer Inc. (NYSE:PFE) saw its price target lowered by Bank of America to $27 from $28 due to steeper COVID-19 franchise erosion and focus shifting to obesity strategy. Investors await Metsera trial results to assess market positioning. On December 17, positive trial results were announced for PADCEV and Keytruda combination for bladder cancer treatment.

The Phase 3 EV-304 trial showed significant improvement in event-free survival and overall survival for muscle-invasive bladder cancer patients with the PADCEV and Keytruda combination. The trial also met its secondary endpoint of pathologic complete response rate, positioning the combination as a potential standard of care for MIBC patients globally. Bladder cancer affects over 614,000 patients annually.

Pfizer Inc. (NYSE:PFE) is a biopharmaceutical company that develops, manufactures, and distributes pharmaceutical products worldwide. While PFE is a potential investment, some AI stocks may offer greater upside potential and less downside risk. Investors looking for undervalued AI stocks can explore the market for opportunities that align with current trends.

For more insights on potential investment opportunities, check out reports on stocks that are projected to double in three years and hidden AI stocks with growth potential. This article is originally published on Insider Monkey.

Read more at Yahoo Finance: BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera